| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| L R Gowing, R L Ali, P Christie, J M Whit. Therapeutic use of cannabis: clarifying the debate. Drug and alcohol review. vol 17. issue 4. 2005-10-31. PMID:16203511. |
at present the evidence is limited, it mostly relates to the use of synthetic cannabinoids, and much of it fails to compare cannabis with the best therapies available for the conditions of interest. |
2005-10-31 |
2023-08-12 |
Not clear |
| L R Gowing, R L Ali, P Christie, J M Whit. Therapeutic use of cannabis: clarifying the debate. Drug and alcohol review. vol 17. issue 4. 2005-10-31. PMID:16203511. |
further research is required to clarify the efficacy of pure, synthetic cannabinoids compared to cannabis, the most effective route of administration, and the importance of delivering a known dose. |
2005-10-31 |
2023-08-12 |
Not clear |
| Sonja Ständer, Martin Schmelz, Dieter Metze, Thomas Luger, Roman Rukwie. Distribution of cannabinoid receptor 1 (CB1) and 2 (CB2) on sensory nerve fibers and adnexal structures in human skin. Journal of dermatological science. vol 38. issue 3. 2005-10-27. PMID:15927811. |
cannabinoid receptors mediate the psychopharmacological action of marijuana and have been localized in the central and peripheral nervous system as well as on cells of the immune system. |
2005-10-27 |
2023-08-12 |
human |
| Andrea L Small-Howard, Lori M N Shimoda, Chaker N Adra, Helen Turne. Anti-inflammatory potential of CB1-mediated cAMP elevation in mast cells. The Biochemical journal. vol 388. issue Pt 2. 2005-10-24. PMID:15669919. |
cannabinoids are broadly immunosuppressive, and anti-inflammatory properties have been reported for certain marijuana constituents and endogenously produced cannabinoids. |
2005-10-24 |
2023-08-12 |
Not clear |
| Zizhong Li, Andrew Gifford, Qian Liu, Rajesh Thotapally, Yu-Shin Ding, Alexandros Makriyannis, S John Gatle. Candidate PET radioligands for cannabinoid CB1 receptors: [18F]AM5144 and related pyrazole compounds. Nuclear medicine and biology. vol 32. issue 4. 2005-10-18. PMID:15878505. |
the mammalian brain contains abundant g protein-coupled cannabinoid cb(1) receptors that respond to delta(9)-tetrahydrocannabinol, the active ingredient of cannabis. |
2005-10-18 |
2023-08-12 |
Not clear |
| Kazuhisa Matsuda, Yukio Mikami, Kazunori Takeda, Shoji Fukuyama, Shinichi Egawa, Makoto Sunamura, Ikurou Maruyama, Seiki Matsun. The cannabinoid 1 receptor antagonist, AM251, prolongs the survival of rats with severe acute pancreatitis. The Tohoku journal of experimental medicine. vol 207. issue 2. 2005-10-14. PMID:16141678. |
cannabinoid means a mind-active material in cannabis (marijuana). |
2005-10-14 |
2023-08-12 |
rat |
| Carol Hamelink, Aidan Hampson, David A Wink, Lee E Eiden, Robert L Eska. Comparison of cannabidiol, antioxidants, and diuretics in reversing binge ethanol-induced neurotoxicity. The Journal of pharmacology and experimental therapeutics. vol 314. issue 2. 2005-09-30. PMID:15878999. |
because the nonpsychoactive cannabinoid cannabidiol (cbd) was previously shown in vitro to prevent glutamate toxicity through its ability to reduce oxidative stress, we evaluated cbd as a neuroprotectant in a rat binge ethanol model. |
2005-09-30 |
2023-08-12 |
rat |
| Jonathan F Fay, Thomas D Dunham, David L Farren. Cysteine residues in the human cannabinoid receptor: only C257 and C264 are required for a functional receptor, and steric bulk at C386 impairs antagonist SR141716A binding. Biochemistry. vol 44. issue 24. 2005-09-26. PMID:15952782. |
the human neuronal cannabinoid receptor (cb1) is a g-protein-coupled receptor (gpcr) triggered by the psychoactive ingredients in marijuana, as well as endogenous cannabinoids produced in the brain. |
2005-09-26 |
2023-08-12 |
human |
| J Ludovic Croxford, Takashi Yamamur. Cannabinoids and the immune system: potential for the treatment of inflammatory diseases? Journal of neuroimmunology. vol 166. issue 1-2. 2005-09-20. PMID:16023222. |
the presence of cannabinoid receptors on cells of the immune system and anecdotal and historical evidence suggesting that cannabis use has potent immuno-modulatory effects, has led to research directed at understanding the function and role of these receptors within the context of immunological cellular function. |
2005-09-20 |
2023-08-12 |
Not clear |
| C Trebst, M Stange. [Cannabinoids in multiple sclerosis -- therapeutically reasonable?]. Fortschritte der Neurologie-Psychiatrie. vol 73. issue 8. 2005-09-14. PMID:16052440. |
anecdotal reports from patients with multiple sclerosis (ms) experiencing relief of their spasticity and pain after smoking marihuana have prompted discussions about a potential therapeutic application of cannabis preparations in ms. only recently the first large, multicenter, double-blind, placebo controlled study was conducted evaluating the use of cannabinoids for treatment of spasticity and other symptoms related to ms. based on this trial and previous uncontrolled observations together with insights from basic research and animal experiments there is reasonable evidence for the therapeutical employment of cannabinoids in the treatment of ms related symptoms. |
2005-09-14 |
2023-08-12 |
Not clear |
| Sara González, Maribel Cebeira, Javier Fernández-Rui. Cannabinoid tolerance and dependence: a review of studies in laboratory animals. Pharmacology, biochemistry, and behavior. vol 81. issue 2. 2005-09-08. PMID:15919107. |
since the discovery in the 1990s of the endocannabinoid signaling system as the target for the action of plant-derived cannabinoids, many studies have addressed these two questions in laboratory animals and, although the results have resulted controversial in various aspects, the following conclusions seem evident: (i) prolonged exposure to plant-derived, synthetic or endogenous cannabinoid agonists in laboratory animals is currently associated with the development of tolerance for most of their pharmacological effects, (ii) tolerance is essentially due to adaptative phenomena consisting in pharmacodynamic events (down-regulation/desensitization of cannabinoid receptors), although some evidence exist on additional pharmacokinetic responses, (iii) the discontinuation of chronic cannabinoid treatment does not elicit abstinence responses spontaneously in most of the cases, presumably because the pharmacokinetic characteristics of cannabinoids, but these responses may be elicited after the blockade of cannabinoid cb1 receptors in cannabinoid-tolerant animals, (iv) these abstinent responses include mainly somatic signs and changes in various molecular processes affected during the abstinence to other drugs although the magnitude of these changes was currently lower in the case of cannabinoids, and (v) cannabinoid-tolerant animals do not appear to be more vulnerable to reinforcing properties of morphine, although the manipulation of the endocannabinoid signaling might serve to treat cannabis addiction and, in particular, the addiction to other drugs such as alcohol, nicotine or opioids. |
2005-09-08 |
2023-08-12 |
Not clear |
| Jonathon C Arnol. The role of endocannabinoid transmission in cocaine addiction. Pharmacology, biochemistry, and behavior. vol 81. issue 2. 2005-09-08. PMID:15925401. |
while animal research suggests cannabis use may precipitate cocaine relapse, cross-sensitization between cannabinoids and cocaine has not been demonstrated and cb1 receptors do not mediate behavioral sensitization to cocaine. |
2005-09-08 |
2023-08-12 |
human |
| Zuzana Justinova, Steven R Goldberg, Stephen J Heishman, Gianluigi Tand. Self-administration of cannabinoids by experimental animals and human marijuana smokers. Pharmacology, biochemistry, and behavior. vol 81. issue 2. 2005-09-08. PMID:15932767. |
self-administration of cannabinoids by experimental animals and human marijuana smokers. |
2005-09-08 |
2023-08-12 |
mouse |
| Zuzana Justinova, Steven R Goldberg, Stephen J Heishman, Gianluigi Tand. Self-administration of cannabinoids by experimental animals and human marijuana smokers. Pharmacology, biochemistry, and behavior. vol 81. issue 2. 2005-09-08. PMID:15932767. |
cannabinoids, which are usually abused by humans in the form of marijuana, have become the most frequently abused illicit class of drugs in the united states. |
2005-09-08 |
2023-08-12 |
mouse |
| Zuzana Justinova, Steven R Goldberg, Stephen J Heishman, Gianluigi Tand. Self-administration of cannabinoids by experimental animals and human marijuana smokers. Pharmacology, biochemistry, and behavior. vol 81. issue 2. 2005-09-08. PMID:15932767. |
the early elucidation of the structure and stereochemistry of delta-9-tetrahydrocannabinol (thc) in 1964, which is now recognized as the principal psychoactive ingredient in marijuana, activated cannabinoid research worldwide. |
2005-09-08 |
2023-08-12 |
mouse |
| José Antonio Ramos, Sara González, Onintza Sagredo, María Gómez-Ruiz, Javier Fernández-Rui. Therapeutic potential of the endocannabinoid system in the brain. Mini reviews in medicinal chemistry. vol 5. issue 7. 2005-09-01. PMID:16026307. |
cannabinoids have been predominantly considered as the substances responsible of the psychoactive properties of marijuana and other derivatives of cannabis sativa. |
2005-09-01 |
2023-08-12 |
Not clear |
| José Antonio Ramos, Sara González, Onintza Sagredo, María Gómez-Ruiz, Javier Fernández-Rui. Therapeutic potential of the endocannabinoid system in the brain. Mini reviews in medicinal chemistry. vol 5. issue 7. 2005-09-01. PMID:16026307. |
however, these compounds are now being also considered for their therapeutic potential, since the term "cannabinoid" includes much more compounds than those present in cannabis sativa derivatives. |
2005-09-01 |
2023-08-12 |
Not clear |
| Balapal S Basavarajappa, Basalingappa L Hungun. Role of the endocannabinoid system in the development of tolerance to alcohol. Alcohol and alcoholism (Oxford, Oxfordshire). vol 40. issue 1. 2005-08-31. PMID:15550443. |
the identification of a g-protein-coupled receptor, namely, the cannabinoid receptor (cb(1) receptor), which was activated by delta(9)-tetrahydrocannabinol (delta(9)-thc), the major psychoactive component of marijuana, led to the discovery of endogenous cannabinoid agonists. |
2005-08-31 |
2023-08-12 |
mouse |
| Malcolm Begg, Pál Pacher, Sándor Bátkai, Douglas Osei-Hyiaman, László Offertáler, Fong Ming Mo, Jie Liu, George Kuno. Evidence for novel cannabinoid receptors. Pharmacology & therapeutics. vol 106. issue 2. 2005-08-30. PMID:15866316. |
cannabinoids, including the bioactive constituents of the marijuana plant, their synthetic analogs, and endogenous lipids with cannabinoid-like activity, produce their biological effects by interacting with specific receptors. |
2005-08-30 |
2023-08-12 |
Not clear |
| S A Varvel, D T Bridgen, Q Tao, B F Thomas, B R Martin, A H Lichtma. Delta9-tetrahydrocannbinol accounts for the antinociceptive, hypothermic, and cataleptic effects of marijuana in mice. The Journal of pharmacology and experimental therapeutics. vol 314. issue 1. 2005-08-26. PMID:15831444. |
the present experiments assessed the cannabinoid activity of marijuana smoke exposure in mice and tested the hypothesis that delta9-thc mediates these effects through a cb1 receptor mechanism of action. |
2005-08-26 |
2023-08-12 |
mouse |